The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 January 2012
|
|
- Marshall Pierce
- 5 years ago
- Views:
Transcription
1 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 January 2012 EPIDUO, gel Tube of 30 g (CIP code: ) Tube of 60 g (CIP code: ) Applicant: GALDERMA Benzoyl peroxide Adapalene List I ATC code: D10AD53 Date of Marketing Authorisation: 23 January 2008 (decentralised procedure) Reason for request: Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use. Medical, Economic and Public Health Assessment Division 1/14
2 1 CHARACTERISTICS OF THE MEDICINAL PRODUCT 1.1. Active ingredient Benzoyl peroxide 2.5% Adapalene 0.1% 1.2. Indication Cutaneous treatment of acne vulgaris when comedones, papules and pustules are present Dosage EPIDUO gel should be applied to the entire acne affected areas once a day in the evening on a clean and dry skin. A thin film of gel should be applied, with the fingertips, avoiding the eyes and lips. If irritation occurs, the patient should be directed to apply non-comedogenic moisturizers, to space out the applications of EPIDUO gel (e.g., every other day), to suspend use temporarily or to discontinue use completely. The duration of treatment should be determined by the doctor based on a clinical examination. The first signs of clinical improvement usually appear after 1 to 4 weeks of treatment. The safety and effectiveness of EPIDUO have not been studied in children below 12 years of age. 2/14
3 2 SIMILAR MEDICINAL PRODUCTS 2.1. ATC Classification (2011) D: Dermatologicals D10: Anti-acne preparations D10A: Anti-acne preparations for topical use D10AD: Retinoids for topical use in acne D10AD53: Adapalene combinations 2.2. Medicines in the same therapeutic category This is the only combination of adapalene and benzoyl peroxide. Proprietary medicinal products containing adapalene as their sole active ingredient are DIFFERINE cream and gel (moderate AB), and their generics. Proprietary medicinal products qualifying for reimbursement and containing benzoyl peroxide as their only active ingredient are the following: CUTACNYL gel 2.5%, 5% and 10% (moderate AB) ECLARAN gel 5% and 10% (moderate AB) PANNOGEL gel 5% and 10% (moderate AB) PANNOXYL gel 5% and 10% (moderate AB) 2.3. Medicines with a similar therapeutic aim The other anti-acne proprietary medicinal products for local administration are based on tretinoin alone or in combination with a local antibiotic, or local antibiotics alone. There are acne medicines for systemic administration, in particular cyclines, non-androgenic hormonal treatments, and isotretinoin. 3 USAGE DATA The product has been on the market since Until now there has been no application for its registration. According to IMS data (moving annual total August 2010), 119,000 prescriptions were issued for EPIDUO gel. In over 99% of cases the diagnosis was acne, and in 89% of cases the prescription was made out by a dermatologist. 3/14
4 4 ANALYSIS OF AVAILABLE DATA The company provided 7 clinical studies evaluating the efficacy and tolerance of EPIDUO gel, a fixed-dose combination of adapalene 0.1% and benzoyl peroxide 2.5%. - three studies comparing EPIDUO to each of the active ingredients taken separately and to placebo in moderate acne, - two studies comparing EPIDUO gel in combination with one cycline versus the same cycline on its own in moderate to severe or severe acne; - one study comparing EPIDUO gel versus placebo in maintenance treatment; - one 52-week non-comparative tolerance study Studies of EPIDUO gel versus each of its ingredients and versus placebo Study by Thiboutot 1 This was a multicentre, randomised, double-blind superiority study conducted in the United States; it compared the efficacy and tolerance of EPIDUO gel with adapalene 0.1% on its own, with benzoyl peroxide 2.5% (BP) on its own and with placebo applied once a day for 12 weeks. The inclusion and non-inclusion criteria relating to the severity of the acne were: - presence of 30 to 100 retentional lesions and 20 to 50 inflammatory lesions on the face. - severe forms of acne requiring treatment with isotretinoin were not included. Two co-primary efficacy endpoints were: - success rate defined as the percentage of patients with an IGA 2 score of 0 or 1. - percentage reduction in the number of total lesions (inflammatory + retentional + other) The superiority of EPIDUO gel for each of these criteria needed to be demonstrated for the study to be regarded as conclusive. Results: Number of patients included: 517 The mean age of the patients was 16 years. The acne was moderate (IGA = 3) in over 75% of the patients. The other patients mainly had mild forms of acne (between 10% and 19%, depending on the groups). In women, no information was given about possible contraception. At 12 weeks the results for the two co-criteria were as follows (see Table 1): - the success rate was higher among the patients treated with the EPIDUO gel fixed-dose combination (27.5%) than those receiving adapalene (15.5%; p = 0.008), BP (15.4%; p = 0.003) or placebo (9.9%; p = 0.002). - the median percentage reduction in the number of total lesions in relation to inclusion was higher with EPIDUO gel (-51.0%) than with adapalene (-35.4%; p < 0.001). BP (-35.6%; p < 0.001) and placebo (-31.0%; p < 0.001). 1 Thiboutot DM et al. Adapalene-benzoyl peroxide, a new fixed-dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: The IGA (Investigator Global Assessment) score is a 6-point scale from 0 to 5 (0 = Clear: residual hyperpigmentation and erythema may be present. 1 = Almost clear: a few scattered comedones and a few small papules. 2 = Mild: some comedones and some papules and pustules present. No nodules. 3 = Moderate: many comedones, papules and pustules present. One nodule may be present. 4 = Severe: covered with comedones, numerous papules and pustules and few nodules and cysts may be present. 5 = Very severe: highly inflammatory acne covering the face with nodules and cysts present). 4/14
5 Table 1: Results for the 2 primary criteria at week 12 (ITT) EPIDUO gel Adapalene BP Placebo Number of patients included: Number of drop-outs Success rate (%) p * Median reduction in the number of total lesions (%) * p vs EPIDUO gel p * - < < < Study by Gollnick 3 This was a multicentre, randomised, double-blind superiority study conducted in the United States, Canada and Poland; it compared the efficacy and tolerance of adapalene 1% - BP 2.5% combination with adapalene 0.1% on its own, with BP 2.5% on its own and with placebo, applied once a day for 12 weeks in moderate acne. Only cases of moderate acne were included (IGA 3); 30 to 100 retentional lesions and 20 to 50 inflammatory lesions on the face needed to be present. Three co-primary efficacy endpoints were envisaged: - success rate defined as the percentage of patients with an IGA score of 0 or 1; - percentage reduction in the number of inflammatory lesions; - percentage reduction in the number of non-inflammatory lesions. The superiority of EPIDUO gel needed to be demonstrated for all of these criteria for the study to be regarded as conclusive. Results: Number of patients included: 1670, of whom 1459 completed the study. The mean age of the patients was 19 years. The initial number of inflammatory lesions was 26 to 27 depending on the groups and the number of retentional lesions from 45 to 46. Oestroprogestogen contraception was in place in 5.3% of the total patients included, with no details regarding the type of pill. At week 12, a difference between the groups was observed for the three primary endpoints (see Table 2): - the success rate was higher in the patients treated with EPIDUO gel (37.9%) than with adapalene (21.8%), BP (26.7%) or placebo (17.9%) (p < 0.001). - The difference in terms of the median variation in the number of lesions was three inflammatory lesions and four non-inflammatory lesions between EPIDUO gel versus adapalene and two inflammatory lesions and five non-inflammatory lesions between EPIDUO gel versus BP. 3 Gollnick HP. Adapalene-benzoyl peroxide, a unique fixed-dose combination topical gel for the treatment of acne vulgaris: a transatlantic, randomized, double-blind, controlled study in 1670 patients. Br J Dermatol 2009; 161: /14
6 Table 2: Results for the three primary criteria at week 12 (ITT) EPIDUO gel Adapalene BP Placebo Number of patients Drop-outs Success rate (%) p * - < < < Median variation in the number of inflammatory lesions p * - < < < Median variation in the number of noninflammatory lesions p * - < < < * p for the comparison vs EPIDUO gel Study (unpublished) This was a multicentre, randomised, double-blind superiority study conducted in the United States, Canada and Puerto Rico; following the same protocol as the Gollnick, it compared the efficacy and tolerance of EPIDUO gel with adapalene 0.1% on its own, BP 2.5% on its own, and with placebo, applied once a day for 12 weeks in moderate acne. Only cases of moderate acne were included (IGA 3); 30 to 100 retentional lesions and 20 to 50 inflammatory lesions on the face needed to be present. Three co-primary efficacy endpoints were envisaged: - success rate defined as the percentage of patients with an IGA score of 0 or 1; - percentage reduction in the number of inflammatory lesions; - percentage reduction in the number of non-inflammatory lesions. The superiority of EPIDUO gel for each of these criteria needed to be demonstrated for the study to be regarded as conclusive. Results: Number of patients included: 1668, of whom 1429 completed the study. The mean age of the patients was 18 years. The number of inflammatory lesions was 27 in the four groups and the number of non-inflammatory lesions was 44 to 47 depending on the groups. Oestroprogestogen contraception was in place in 3.1% of the total patients included, with no details regarding the type of pill. At week 12, the results of study in moderate acne showed a difference between the groups for two of the three co-primary endpoints (see Table 3): - the success rate was significantly higher in the patients receiving EPIDUO gel (30.1%) than in those receiving adapalene (19.8%; p < 0.001), BP (22.2%; p = 0.006) or placebo (11.3%; p < 0.001). - the difference in terms of the median variation in the number of lesions was two inflammatory lesions and two non-inflammatory lesions versus adapalene and four non-inflammatory lesions versus BP on its own. - on the other hand, there was not shown to be any difference in the median variation in the number of inflammatory lesions versus BP on its own. 6/14
7 The superiority of EPIDUO gel with respect to BP in this study has therefore not been demonstrated. Table 3: Results for the three primary criteria at week 12 (ITT) EPIDUO gel Adapalene BP Placebo Number of patients Drop-outs Success rate 30.1% 19.8% 22.2% 11.3% p * - < < Median variation in the number of inflammatory lesions p * - < NS < Median variation in the number of noninflammatory lesions p * - < < < * p for the comparison vs EPIDUO gel Grouped results for the Thiboutot and Gollnick studies and Study The applicant has grouped together and reanalysed the results of the three studies described above, stratifying them into three sub-groups according to the number of total lesions. The aim was to show a difference in efficacy versus placebo depending on the number of initial lesions. This analysis is not described on account of its methodology Studies with EPIDUO gel combined with a cycline versus cycline on its own TEAM study 4 in combination with lymecycline (moderate to severe acne) This multicentre, randomised, double-blind superiority study assessed the efficacy and tolerance of EPIDUO gel in combination with lymecycline 300 mg versus placebo in combination with lymecycline 300 mg on its own, applied once daily for 12 weeks in the treatment of moderate to severe acne. The patients included had to have facial acne with an IGA score of 3 or 4. They also had to have at least 20 inflammatory lesions and between 30 and 120 retentional lesions. The primary efficacy endpoint was the median percentage reduction in the number of total lesions at week 12. The success rate was measured as one of the secondary endpoints (percentage of patients with an IGA score of 0 or 1). Results: Number of patients included: Gold LS. Adapalene-BPO Study Group. A North American study of adapalene-benzoyl peroxide combination gel in the treatment of acne. Cutis 2009; 84: /14
8 At inclusion, 83% of the patients had an IGA score of 3 (moderate acne), 17% of the patients had an IGA of 4 (severe acne). In women, no information was given about possible contraception. At 12 weeks, the median percentage reduction in the total lesions was -74% in the EPIDUO gel + lymecycline group versus -56% in the placebo + lymecycline arm (p < 0.001) (see Table 4). Table 4: Results for the primary endpoint (ITT) EPIDUO gel + lymecycline Placebo + lymecycline Number of patients included Median reduction in the number of total lesions (%) p < The success rate (secondary endpoint) was greater in the EPIDUO gel + lymecycline group (47.6%) than in the placebo + lymecycline group (33.7%) (p = 0.002) Access 1 Study in combination with doxycycline (severe acne) This multicentre, randomised, double-blind superiority study evaluated the efficacy and tolerance of EPIDUO gel fixed-dose combination with doxycycline 100 mg versus doxycycline 100 mg on its own, applied once daily for 12 weeks in the treatment of severe acne. The patients included had to have facial acne with an IGA score of 4. They also had to have at least 30 inflammatory lesions and a maximum of 120 non-inflammatory lesions. Among the inclusion criteria, women had to be taking effective birth control measures, but had to have stopped taking oestroprogestogen for the treatment of acne at least six months previously. The primary efficacy endpoint was the median percentage reduction in the number of total lesions at week 12. Among the secondary endpoints was the success rate defined as the percentage of patients having an IGA of 0 or 1 at week 12. Results: Number of patients included: 459 The mean age was 18 years On inclusion, the mean number of lesions was similar for total, inflammatory and retentional lesions. At 12 weeks, the median percentage reduction in the number of total lesions was greater under EPIDUO gel in combination with doxycycline (-64%) than under doxycycline on its own (-41%) (p < 0.001) (see Table 5). Table 5: Results for the primary criterion at week 12 (ITT) EPIDUO gel + doxycycline Placebo + doxycycline Number of patients included Median % reduction in the -64% -41% number of total lesions p < /14
9 The success rate (secondary endpoint) was greater in the EPIDUO gel + doxycycline group (31.5%) than in the placebo group (8.4%) (p < 0.001) Studies with EPIDUO gel in maintenance treatment Access 2 study in maintenance treatment This was a randomised double-blind study which over a 24-week period compared EPIDUO gel with placebo as maintenance treatment in patients with severe facial acne treated in the Access 1 study and whose improvement was judged good by investigators at the conclusion of the Access 1 study. The primary efficacy endpoint was the percentage of patients who maintained the efficacy obtained in terms of the number of total lesions at week 24. Maintained success was defined as maintaining at least 50% of the improvement obtained during the course of the treatment administered previously in terms of the number of total lesions. Maintenance of efficacy was also studied with inflammatory and non-inflammatory lesions. Among the inclusion criteria, women using oestroprogestogen contraception had to have started it at least 6 months previously. Results: Number of patients included: 459 Mean age: 18 years Patients on oestroprogestogen contraception: 5.1% On inclusion, half the patients (48.6%) were classed mild (IGA 2), 31.7% almost clear (IGA 1) and 19.3% moderate (IGA 3). After 24 weeks of maintenance treatment, maintenance of the success rate obtained during the preceding treatment in terms of the number of total lesions was superior in the case of patients treated with EPIDUO gel (78.9%) versus placebo (45.8%) (< ) (see Table 6). Table 6: Access 2 study: severity level and results for the primary endpoint after 24 weeks of maintenance treatment Adapalene BP Placebo Number of patients included % maintained success in terms of the number of total lesions 78.9% 45.8% p < Among the secondary endpoints, maintenance of the success rate at week 24 was also demonstrated in terms of the inflammatory lesions [78% versus 48% (p = )] and retentional lesions [78% versus 43% (p < )] in comparison with placebo Adverse effects Safety study (unpublished) The non-comparative study assessed the safety of EPIDUO gel applied once daily for 52 weeks. On inclusion the patients had to have facial acne with an IGA score of 3. They also had to have between 20 and 50 inflammatory lesions and between 30 and 100 retentional lesions. 9/14
10 Local tolerance was evaluated using a 4-point score for the following four signs: burns/dryness/redness/pruritus Information about general symptoms was also collected as well as performing routine biological tests. Results: The number of patients included that had received the treatment at least once was 452. No patients withdrew from the study for lack of efficacy, 2% withdrew on account of adverse events. The following side effects were common (> 1%): redness, erythema, peeling, cutaneous discomfort, pruritus, burning or irritation at the product application site and sunburn, most of them occurring during the first three months (84%). No serious adverse effects were identified. Category Patient with 1 treatmentrelated adverse effect Study period (months) 0 to 3 (N = 452) 3 to 6 (N = 397) 6 to 9 (N = 366) 9 to 12 (N = 334) 127 (28.1%) 16 (4.0%) 11 (3.0%) 5 (1.5%) Dermatological adverse effect 94 (20.8%) 8 (2.0%) 8 (2.2%) 4 (1.2%) Non-dermatological adverse effect 94 (20.8%) 8 (2.0%) 8 (2.2%) 4 (1.2%) Tolerance in efficacy studies During the course of the grouped tolerance analysis in the three studies (those by Thiboutot and by Gollnick, and study 18087), the proportion of patients presenting at least one adverse event regarded as treatment-related was greater with EPIDUO gel (21%) than with each of its ingredients on their own: adapalene (15%), BP (8.5%), or with placebo (6%). Most of these adverse events were of a dermatological nature (irritation, dry skin, etc.) and of mild to moderate intensity. For the most part they occurred at the start of the study. During the course of studies of moderate to severe acne in combination with a cycline, the safety profile between adapalene-bp and vehicle groups also included local adverse effects such as burning sensation and itching, occasionally severe (7% of the local effects reported in the Access 1 study), in the group treated with EPIDUO gel SPC In addition to the common cutaneous adverse effects reported in the studies, a change in the SPC of January 2011 refers to the possibility of allergic contact dermatitis and facial swelling whose frequency could not be determined in the absence of sufficient data. In the "Pregnancy" section of the SPC it states that due to the limited available data and because a weak cutaneous passage of adapalene is possible, EPIDUO gel should not be used during pregnancy. In case of unexpected pregnancy, treatment should be discontinued Conclusion In three studies, EPIDUO gel was compared with each of its active ingredients used on their own and with placebo in mild to moderate acne. Its efficacy was judged on several criteria: on the reduction in the number of lesions and success (percentage of patients with a score of 0 or 1 on a 6-point scale). Based on these criteria, the adapalene/bp combination proved superior in the three studies to adapalene and to placebo. The adapalene/bp combination 10/14
11 was superior to adapalene on its own and to placebo in the three studies and to BP in two studies (in the third study, EPIDUO gel was not superior to BP). In moderate to severe acne and in severe acne, EPIDUO gel/cycline proved superior to cycline alone in two studies as regards the reduction in the number of total lesions; -74.1% vs -56.8% (p < 0.001) with lymecycline and -64% vs -41% (p < 0.001) with doxycycline. The difference in efficacy between EPIDUO gel and each of its active ingredients is small. In the maintenance treatment of severe acne, EPIDUO gel over 24 weeks was superior to placebo in maintaining the success rate obtained with doxycycline as regards the number of total lesions (78.9% versus 45.8%); (p < ). As none of the studies compared the fixed-dose combination of EPIDUO gel with the two active ingredients applied separately, the synergy of the two active ingredients applied at the same time was not proven. There were more patients who had had at least one adverse event with EPIDUO gel than with the active ingredients used on their own: 21% with EPIDUO gel, 15% with adapalene, 8.5% with BP and 6% with placebo. Similarly, there were more treatment drop-outs in the EPIDUO gel group than in the groups using the ingredients on their own. Local cutaneous effects (irritation, sensation of burning, etc.) were more common. Cases of facial oedema were also reported (SPC). The fixed-dose combination of 2.5% benzoyl peroxide and 1% adapalene was not always suitable for the type of acne encountered, according to whether retentional or inflammatory lesions predominated. 11/14
12 5 TRANSPARENCY COMMITTEE CONCLUSIONS 5.1. Actual benefit Acne is not a serious disease, but its psychological impact can be considerable in its severe forms. These proprietary products fall under the category of symptomatic treatment. The efficacy of EPIDUO is moderate. Local adverse effects are common. The efficacy/adverse effects ratio of EPIDUO gel in this indication is moderate. These proprietary medicinal products are second-line therapies. They are not recommended during pregnancy. Alternatives are available. Public health benefit: Acne is a very common condition. This skin disease is as a rule benign, and though it can have repercussions for patients quality of life, its burden from a public health point of view is slight. The treatment of acne vulgaris does not represent a public health need and the therapeutic need is covered by existing treatments. In light of the clinical trial data, this proprietary medicinal product is not expected to have any impact on morbidity or on quality of life, including in comparison with the coadministration of the separately presented ingredients of the combination. It is not expected, therefore, that the proprietary medicinal product EPIDUO gel will have any public health benefit when used in the treatment of acne vulgaris. The actual benefit of EPIDUO gel is moderate Improvement in actual benefit (IAB) EPIDUO gel does not offer any improvement in actual benefit (IAB V) in comparison to the free combination of each of its active ingredients Therapeutic use Therapeutic strategy for acne 5 Proper hygeine is recommended in every case: - daily or twice-daily cleansing with soap-free hypoallergenic gels or cleansing bars; - daily application of a moisturiser suitable for problem skin. Drug treatment generally takes time, alternating between aggressive therapy (at least three months) and maintenance treatment. The approach to the treatment of minimal to moderate acne depends on its clinical presentation (with either retentional or inflammatory lesions predominating). The retentional component relies principally on topical treatment, while severe forms of acne require a specific therapeutic approach. 5 Afssaps. Topical and systemic treatment of acne. Good practice recommendations. November Publications/Recommendations/Medications 12/14
13 Predominantly retentional acne - 0.1% adapalene or 0.025% tretinoin, applied once daily Predominantly inflammatory acne (papulopustular acne) Localised form - first-line treatment: 5% benzoyl peroxide applied once daily; - in cases of benzoyl peroxide intolerance: either 0.1% adapalene applied once daily or a topical antibiotic (4% erythromycin or 1% clindamycin) combined with a topical retinoid (0.025% tretinoin or 0.1% adapalene (applied in the evening or alternating morning and evening). Extended and/or slow-developing form - first-line treatment: cyclines (doxycycline 100 mg/day or lymecycline 300 mg/day) orally ( 3 months of continuous treatment); - in case of contraindication to cyclines: erythromycin. It is recommended to combine topical treatment with systemic antibiotic therapy: benzoyl peroxide, or a topical retinoid, or a combination of the two. Combining a topical with systemic antibiotic therapy is not recommended. In the event of failed previous treatments: oral isotretinoin (0.5 mg/kg/day by way of an attack dose up to a cumulative dose of between 100 and 150 mg/kg) (see MA). In cases of contraindication, inefficacy or poor tolerance of other systemic treatments, zinc gluconate may be prescribed for mild to moderate inflammatory acne. Nodular acne and other severe forms - oral isotretinoin see SPC for warnings regarding treatment with isotretinoin Maintenance treatment - topical retinoids, in particular 0.1% adapalene, possibly in combination with oral zinc gluconate; - in women wishing to use contraception: non-androgenic hormone therapy Place of EPIDUO gel in the treatment strategy In localised forms of acne EPIDUO gel should be prescribed as a second-line treatment after the failure of an initial topical treatment. In extended forms, EPIDUO gel is recommended in combination with oral antibiotics, as is each of the two products used on its own. The choice between these strategies will depend on the characteristics of the lesions and on the prescriber s choice Target population The prevalence of acne in 12 to 20-year-old adolescents is estimated to be depending on the study 6,7 between 72% and 91%, regardless of the severity of the disease. In other words, there are between 5.0 and 5.7 million individuals aged from 12 to 20 years suffering from acne. 6 Ghodsi SZ et al. Prevalence, severity and severity risk factors of acne in high school pupils: a community-based study. J Invest Dermatol 2009; 129: Daniel F. Epidémiologie descriptive de l acné dans la population scolarisée en France métropolitaine pendant l automne Ann Dermatol Vénéréol 2000; 127: /14
14 Acne can also affect adults. According to an English publication, 8 12% of women and 3% of men over the age of 25 could have mild to moderate acne. Extrapolated to the French population, this would mean there are 1.8 million adults between the ages of 20 and 49 who are suffering from acne. In all, there are some 7 million people with acne Transparency Committee recommendations The transparency Committee recommends inclusion on the list of medicines refundable by National Health Insurance and on the list of medicines approved for hospital use and various public services in the indications and at the dosages given in the Marketing Authorisation Packaging: Appropriate for the prescription conditions Reimbursement rate: 30% 8 Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol 1999; 41: 4: /14
ACNE BOOT CAMP TOPICAL THERAPY BASICS
ACNE BOOT CAMP TOPICAL THERAPY BASICS Lawrence J Green, MD Associate Clinical Professor of Dermatology George Washington University School of Medicine Washington DC Relevant Disclosures Investigator -Allergan,
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 January 2007 DICLOFENAC SODIUM MIKA PHARMA 4%, skin spray solution 7.5 g Vial (CIP: 362 261-8) 12.5 g Vial (CIP:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 GRAZAX 75 000 SQ-T, oral lyophilisate B/30 (CIP: 378 011-6) B/100 (CIP code: 378 012-2) B/90 (CIP code:
More informationEvidence-based Clinical Practice Guidelines for Treatment of Acne and Rosacea in Canada. Catherine Zip Nov 10, 2016
Evidence-based Clinical Practice Guidelines for Treatment of Acne and Rosacea in Canada Catherine Zip Nov 10, 2016 Acne Acne Classification Type Comedonal Mild-to-moderate papulopustular acne Severe Description
More informationTRANSPARENCY COMMITTEE OPINION. 21 October 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 October 2009 TEMERIT DUO 5 mg/12.5 mg, film-coated tablets Pack of 30 (CIP: 393 976-9) Pack of 90 (CIP: 393 977-5)
More informationACNE. Jason M Cheyney, MPAS, PA-C Dermatologic Surgery Specialists Macon, Ga 31211
ACNE Jason M Cheyney, MPAS, PA-C Dermatologic Surgery Specialists Macon, Ga 31211 Pathogenesis of Acne Causative Factors Therapy On the horizon Approximately 45 million Americans have acne It is often
More informationACNE UPDATE 2017 FACULTY DISCLOSURE ACNE UPDATE
ACNE UPDATE 2017 PATRICIA TREADWELL, M.D. PROFESSOR OF PEDIATRICS AND DERMATOLOGY IU SCHOOL OF MEDICINE FACULTY DISCLOSURE I have no relevant financial relationships with the manufacturer(s) of any commercial
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 1 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 1 October 2008 EFFEXOR SR 37.5 mg prolonged-release capsule B/30 (CIP: 346 563-3) EFFEXOR SR 75 mg prolonged-release
More informationACNE. What are the aims of this leaflet?
ACNE What are the aims of this leaflet? This leaflet has been written to help you understand more about acne - what it is, what causes it, what can be done about it and where you can find out more about
More informationAcne Vulgaris. This non promotional presentation has been sponsored and developed by Galderma for UK healthcare professionals only.
Acne Vulgaris [Speaker Name] [Speaker Title] This non promotional presentation has been sponsored and developed by OTH18-07-0203 DOP: August 2018 Learning Objectives Explain the pathophysiology of acne
More informationClinical Study Synopsis for Public Disclosure
Clinical Study Synopsis for Public Disclosure These results are supplied for informational purposes only in the interest of scientific disclosure. The synopsis may include approved and non-approved uses,
More informationAcne vulgaris is a disease of the pilosebaceous unit (i.e., the sebaceous glands and adjacent hair follicle).
Dr. Ghassan Salah Acne is a common, chronic inflammatory disorder of the pilosebaceous unit in which a microcomedo develops as the initial condition. The most common form of acne is acne vulgaris. Other
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 March 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 March 2011 TAREG 3 mg/ml oral solution B/1 160 ml (CIP code: 491 474-8) Applicant: NOVARTIS PHARMA SAS valsartan
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 CARDENSIEL 1.25 mg, film-coated tablet B/30 (CIP code: 352 968-1) CARDENSIEL 2.5 mg, film-coated tablet
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 4 January 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 January 2012 Examination of the dossier for a medicinal product included for a 5-year period starting on 7 January
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2012 ANAPEN 0.50 mg/0.3 ml, solution for injection in pre-filled syringe 1 pre-filled syringe (glass), box of
More informationOpinion 8 January 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 8 January 2014 WYSTAMM 1 mg/ml, oral solution 120 ml vial with syringe for oral administration (CIP: 34009 222 560
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 9 May 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 9 May 2007 RECTOGESIC 4 mg/g, rectal ointment B/1 (CIP 376 537-0) Applicant : PROSTRAKAN PHARMA SAS Glyceryl trinitrate
More informationX-Plain Acne Reference Summary
X-Plain Acne Reference Summary Nearly 17 million people in the United States have acne, making it one of the most common skin diseases in the USA. Although acne is not a serious health threat, severe acne
More informationReview Acne Pathogenesis Clinical Evaluation Treatment Guidelines
Tiffany Herd, MD Pediatric Dermatology Fellow Baylor College of Medicine/Texas Children's Hospital Review Acne Pathogenesis Clinical Evaluation Treatment Guidelines Psychosocial Impact of Acne Acne is
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 27 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 27 May 2009 RASILEZ HCT 150 mg/12.5 mg, film-coated tablets B/30 (CIP code: 392 151-6) RASILEZ HCT 150 mg/25 mg, film-coated
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 5 January 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 5 January 2011 Review of the dossier of the proprietary drugs included on the list of reimbursable medicines for a
More informationACNE VULGARIS: DIAGNOSIS AND TREATMENT
ACNE VULGARIS: DIAGNOSIS AND TREATMENT Federal Bureau of Prisons Clinical Guidance DECEMBER 2017 Clinical guidance is made available to the public for informational purposes only. The Federal Bureau of
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 TROLOVOL 300 mg, film-coated tablet B/30 (CIP: 34009 320 316 9 6) Applicant: IMAXO INN ATC Code (2012)
More informationTopical Retinoids Prior Authorization Criteria Program Summary
Topical Retinoids Prior Authorization Criteria Program Summary OBJECTIVE The intent of the Retinoids Prior Authorization (PA) criteria is to discourage use of the listed target agents for the treatment
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationManagement of Truncal Acne Vulgaris: Current Perspectives on Treatment
DRUG THERAPY TOPICS Management of Truncal Acne Vulgaris: Current Perspectives on Treatment James Q. Del Rosso, DO Acne vulgaris is one of the most common disorders encountered by dermatologists in the
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 13 May 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 13 May 2009 STELARA 45 mg, solution for injection B/1 x 0.5 ml vial (CIP code: 392 586-2) JANSSEN-CILAG Ustekinumab
More informationDuring the last 20 years, the number of topical
THERAPEUTICS FOR THE CLINICIAN Cumulative Irritation Potential of Adapalene 0.1% Cream and Gel Compared With Tretinoin Microsphere 0.04% and 0.1% Jonathan S. Dosik, MD; Kenneth Homer, MS; Stéphanie Arsonnaud
More informationEuropean evidence-based (S3) guideline for the treatment of acne update 2016 short version
DOI: 10.1111/jdv.13776 JEADV ORIGINAL ARTICLE European evidence-based (S3) guideline f the treatment of acne update 2016 sht version A. Nast, 1, *B.Dreno, 2 V. Bettoli, 3 Z. Bukvic Mokos, 4 K. Degitz,
More informationInt. J. Pharm. Sci. Rev. Res., 29(1), November December 2014; Article No. 34, Pages:
Research Article A Comparative Study to Evaluate the Efficacy and Safety of Topical Isotretinoin and Versus Adapalene and in The Treatment of Grade I II Acne Vulgaris of Face Dr. Jyotirmoy Adhikary* 1,
More informationTRANSPARENCY COMMITTEE OPINION. 4 November 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 4 November 2009 RANEXA 375 mg extended release tablet Pack of 60 (CIP: 394 370-7) RANEXA 500 mg extended release tablet
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 OSVAREN 435 mg/235 mg, film-coated tablet Bottle of 180 (CIP: 382 886 3) Applicant: FRESENIUS MEDICAL
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationInternational Journal of Pharma and Bio Sciences
Research Article Pharmacology International Journal of Pharma and Bio Sciences ISSN 0975-6299 COMPARISION OF CLINICAL EFFICACY OF TOPICAL CLINDAMYCIN WITH ADAPALENE AND ADAPALENE ALONE IN TREATMENT OF
More informationOral Antibacterial Therapy for Acne Vulgaris: An Evidence- Based Review
Am J Clin Dermatol DOI 10.1007/s40257-017-0267-z EVIDENCE-BASED REVIEW Oral Antibacterial Therapy for Acne Vulgaris: An Evidence- Based Review Amanda Bienenfeld 1 Arielle R. Nagler 2 Seth J. Orlow 2 Springer
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 June 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 June 2011 SPASFON, film-coated tablets B/30 (CIP code: 309 860-8) SPASFON, suppositories B/10 (CIP code: 309 861-4)
More informationDoxycycline/Minocycline Step Therapy Criteria Program Summary
This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the
More informationTRANSPARENCY COMMITTEE OPINION. 10 December 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 RELISTOR 12 mg/0.6 ml solution for injection 1 vial (CIP: 387 365-1) 2 vials + 2 sterile syringes
More informationTransparency Committee Opinion 8 January 2014
The legally binding text is the original French version Transparency Committee Opinion 8 January 2014 RHINOTROPHYL, nasal spray, solution Vial of 20 ml (CIP: 34009 309 102 6 9) Applicant: JOLLY-JATEL INN
More informationTreatment of adult female acne: a new challenge
DOI: 10.1111/jdv.13188 JEADV REVIEW ARTICLE Treatment of adult female acne: a new challenge B. Dreno* Department of Dermato-Cancerology, University of Nantes, Nantes, France *Correspondence: B. Dreno.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 April 2011 METEOXANE, capsules B/60 (CIP code: 306 693-3) Applicant: IPRAD Simethicone Hydrated phloroglucinol ATC
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE. Opinion. 20 February 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 20 February 2008 DUROGESIC 12 micrograms/hour (2.1 mg/5.25 cm²), transdermal patch Box of 5 sachets (CIP: 369 851-5)
More informationPROCEEDINGS PRACTICAL APPLICATIONS: CASE STUDY REVIEWS* Bernard A. Cohen, MD, FAAP
PRACTICAL APPLICATIONS: CASE STUDY REVIEWS* Bernard A. Cohen, MD, FAAP A HEALTHY 4-WEEK-OLD INFANT WITH ACNE A 4-week-old infant was brought to the pediatrician s office by his parents following the appearance
More informationTo order reprints or e-prints of JDD articles please contact JDD
June 2017 534 VOLUME 16 ISSUE 6 Copyright 2017 ORIGINAL ARTICLE Journal of Drugs in Dermatology The Efficacy and Safety of Azelaic Acid 15% Foam in the Treatment of Truncal Acne Vulgaris Lauren K. Hoffman
More informationTRANSPARENCY COMMITTEE OPINION. 26 November 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 November 2008 CHONDROSULF 400 mg, capsule Box containing 84 capsules (CIP: 335 917-3) CHONDROSULF 400 mg, granules
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 IMUREL 50 mg, film-coated tablet (B/100) (CIP: 34009 364 149 0 7) IMUREL 25 mg, film-coated tablet (B/50)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 Review of the dossier of the medicinal product included on the list of reimbursable medicines for a period
More informationNew Zealand Datasheet. 3 PHARMACEUTICAL FORM DIFFERIN topical cream is a smooth white cream containing 1 mg/g adapalene.
New Zealand Datasheet 1 PRODUCT NAME DIFFERIN 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Adapalene 1 mg/g topical cream 3 PHARMACEUTICAL FORM DIFFERIN topical cream is a smooth white cream containing 1
More informationIndex. derm.theclinics.com. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abnormal wound healing Acne and cybereducation, 131 and Google, 129 131 and online dangers, 131, 132 reliable online resources on, 130 self-proclaimed
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 TAMIK Ge 3 mg, soft capsule B/60 (CIP code: 322 714-1) Applicant: IPRAD dihydroergotamine mesylate ATC
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationTRANSPARENCY COMMITTEE OPINION. 31 January Date of marketing authorisation: 22 March 2005 (centralised marketing authorisation)
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 31 January 2007 ALOXI 250 µg solution for injection B/1 CIP 375,482-8 Applicant: THERABEL LUCIEN PHARMA palonosetron
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 SMECTA, powder for oral solution in sachets 30 sachets of 3.76 g (CIP: 34009 319 230-7 7) 60 sachets
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 December 2008 REBETOL 200 mg capsules Pack of 84 (CIP code: 351 971.9) Pack of 112 (CIP code: 373 277.8) Pack of
More informationThe legally binding text is the original French version
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 26 September 2007 RELENZA 5mg/dose, inhalation powder, in single-dose containers 20 single-dose containers with an
More informationPackage leaflet: Information for the patient. IsotrexIN Gel erythromycin 2% and isotretinoin 0.05%
Package leaflet: Information for the patient IsotrexIN Gel erythromycin 2% and isotretinoin 0.05% Read all of this leaflet carefully before you start using this medicine because it contains important information
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 IKARAN LP 5 mg, tablets B/30 (CIP: 339 287-4) IKARAN Ge 2 mg/ml, oral solution in drops Vial of 50 ml
More informationStieva-A. Tretinoin Preparations
Name of medical preparation Stieva-A cream Stieva-A Tretinoin Preparations Formulations and Strength Topical cream containing tretinoin 0.01 % w/w (0.01 g per 100 g cream) Topical cream containing tretinoin
More informationTRANSPARENCY COMMITTEE OPINION. 15 October 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 October 2008 TANDEMACT 30 mg/20 mg tablets Box of 30 (CIP: 386 566-3) Box of 90 (CIP: 386 568-6) TANDEMACT 30 mg/4
More informationClinical Medicine Insights: Dermatology. Real Word Acne Therapy in Primary Care. Neel Malhotra 1, Timothy E. Pyra 2 and Jaggi Rao 2
Clinical Medicine Insights: Dermatology Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Real Word Acne Therapy in Primary Care Neel Malhotra 1, Timothy
More informationWorld Journal of Pharmaceutical Research
Shraddhamayananda SJIF Impact Factor 5.045 Volume 3, Issue 6, 618-625. Research Article ISSN 2277 7105 EFFICACY OF HOMEOPATHIC MEDICINES IN THE TREATMENT OF ACNE *Swami Shraddhamayananda Ramakrishna Mission
More informationOpinion 6 March 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 6 March 2013 EFFALA 8 mg, medicated plaster B/4 sachets (CIP code: 34009 397 996 4 3) B/8 sachets (CIP code: 34009
More informationOpinion 23 July 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 23 July 2014 ACADIONE 250 mg, sugar-coated tablet Bottle of 120 (CIP: 34009 329 390 7 7) Applicant: SANOFI-AVENTIS
More informationObjective To determine the immediate irritation effects and the irritation power of a particular materials.
SAFETY STUDIES 1.1 Skin Irritation through Open Patch Test 1.2 Skin Irritation through Patch Test. 1.3 Human Skin Irritation Test 1.4 Repeat Open Application Test 1.5 Test For Hypoallergenicity 1.6 Modified
More informationTRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 ERBITUX 2 mg/ml, Solution for infusion 1 bottle of 50 ml (CIP: 565 806 9) Applicant : MERCK LIPHA
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 16 December 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 16 December 2009 MOZOBIL 20 mg/ml, solution for injection Box containing 1 vial (CIP: 397 153-7) Applicant: GENZYME
More informationProspective Study of Risk Factors of Relapse after Treatment of Acne with Oral Isotretinoin
Pharmacology and Treatment Dermatology 26;212:168 176 DOI: 1.1159/9658 Received: February 18, 25 Accepted after revision: September 1, 25 Prospective Study of Risk Factors of Relapse after Treatment of
More informationJEADV SUPPLEMENT ARTICLE
DOI: 10.1111/jdv.13194 JEADV SUPPLEMENT ARTICLE Safety and efficacy of adapalene 0.1% / benzoyl peroxide 2.5% in the long-term treatment of predominantly moderate acne with or without concomitant medication
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 10 February 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 10 February 2010 ADIXONE 50 µg, tablet Box of 30 (CIP: 390 604.3) Box of 60 (CIP: 390 606.6) Box of 90 (CIP: 390 607.2)
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 October 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 October 2006 CUBICIN 350 mg (daptomycin), powder for perfusion solution Box of 1 bottle (CIP code: 567 219-3) CUBICIN
More informationThe legally binding text is the original French version. Opinion 28 May Hospital use (French Social Security Code L )
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 28 May 2014 ADASUVE 9.1 mg, inhalation powder, pre-dispensed B/5 (CIP: 3400958597671) Applicant: BIOPROJET PHARMA
More informationTRANSPARENCY COMMITTEE OPINION. 21 January 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 January 2009 BRIDION 100 mg/ml, solution for injection Box containing 10 x 2 ml bottles, CIP: 573 553-9 Box containing
More informationThe surest route to success in treating acne
Applied Evidence R ESEARCH F INDINGS T HAT A RE C HANGING C LINICAL P RACTICE Management of acne David C. Liao, MD, Naval Hospital Camp Pendleton; Irvine, California Abstract Precise classification methods
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 15 December 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 December 2010 HIROBRIZ BREEZHALER 150 micrograms, inhalation powder, hard capsules B/10 with inhaler (CIP code:
More informationTRANSPARENCY COMMITTEE OPINION. 22 July 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 July 2009 PHOSPHOSORB 660 mg, film-coated tablet Container of 200 (CIP: 381 466-0) Applicant: FRESENIUS MEDICAL
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 SEGLOR 5 mg, hard capsule B/30 (CIP code: 321 899-8) SEGLOR LYOC 5 mg, oral lyophilisate B/30 (CIP code:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationDD PROOFS. Acne vulgaris is a multifactorial skin disorder affecting
June 2014 611 Copyright 2014 ORIGINAL ARTICLES SPECIAL TOPIC Rapid Treatment of Mild Acne With a Novel Skin Care System Containing 1% Salicylic Acid, 10% Buffered Glycolic Acid and Botanical Ingredients
More informationRosacea. This non promotional presentation has been sponsored and developed by Galderma for UK healthcare professionals only.
Rosacea [Speaker Name] [Title] This non promotional presentation has been sponsored and developed by OTH18-07-0214 DOP: September 2018 Learning Objectives To review current guidelines for best practice
More informationOpinion 18 December 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 18 December 2013 LANTUS 100 units/ml, solution for injection in a vial B/1 vial of 10 ml (CIP: 34009 359 464 9 2)
More informationTRANSPARENCY COMMITTEE Opinion 17 September 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 September 2014 VEREGEN 10%, ointment Tube of 15 g (CIP: 34009 222 531 2 1) Applicant: EXPANSCIENCE INN ATC Code
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 28 March 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 28 March 2012 EXFORGE HCT 5 mg/160 mg/12.5 mg, film-coated tablets B/30 (CIP code: 397 327-5) B/56 (CIP code: 397
More informationManagement of Acne in Primary Health Care: The good, the bad and the ugly
Management of Acne in Primary Health Care: The good, the bad and the ugly Marie-Lyne Bournival BSc, PG Dip (Health Sc), MN Nurse Practitioner Hei Hei Health Centre Christchurch, New Zealand Wednesday 29
More informationTherapy Eur J Dermatol 2014; 24(2): 201-9
Therapy Eur J Dermatol 214; 24(2): 21-9 Brigitte DRÉNO 1 Vincenzo BETTOLI 2 Falk OCHSENDORF 3 Alison M. LAYTON 4 Montserrat PEREZ 5 Rada DAKOVIC 6 Harald GOLLNICK 7 1 Dept of Dermato-Cancerology, University
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationDOI /j x
THERAPEUTICS DOI 1.1111/j.1365-2133.27.883.x Double-blind, randomized, placebo-controlled study of a lotion containing triethyl citrate and ethyl linoleate in the treatment of acne vulgaris A. Charakida,
More informationOral Azithromycin Pulse Therapy and Daily Topical Benzoyl Peroxide in the Treatment of Acne Vulgaris: An Open Clinical Trial Study
Journal of Bangladesh College of Physicians and Surgeons Vol. 36, No. 1, January 218 Oral Azithromycin Pulse Therapy and Daily Topical Benzoyl Peroxide in the Treatment of Acne Vulgaris: An Open Clinical
More informationPFIZER INC. GENERIC DRUG NAME and/or COMPOUND NUMBER: 5% Spironolactone Cream/ PF
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationF r e q u e n t l y A s k e d Q u e s t i o n s
Acne who specializes in treating skin problems) about how you can help prevent acne and if treatment would help you. Q: What is acne? A: Acne is a disorder that causes outbreaks of skin lesions commonly
More informationThe legally binding text is the original French version. Opinion 15 May 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 15 May 2013 ARIXTRA 2.5 mg/0.5 ml, solution for injection in pre-filled syringe B/2 (CIP: 34009 359 225 4 0) B/7 (CIP:
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 23 May 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 23 May 2012 OKIMUS, coated tablets B/2 blister strips of 20 tablets (CIP code: 363 666-1) Applicant: BIOCODEX Quinine
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 October 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 October 2011 PEDIAVEN AP-HP G15, solution for infusion 1000 ml of solution in two chamber bag, B/4 (CIP code: 419
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 19 December 2007
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 December 2007 METHADONE AP-HP 1mg, gelatin-coated capsule Box of 7 (CIP: 379 146-2) METHADONE AP-HP 5mg, gelatin-coated
More information